New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;SI;FLO;NOK;UBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
19:36 EDTUBSUBS settles lawsuit related to sale of risky securities, BI says
Subscribe for More Information
10:04 EDTNOKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:09 EDTNOKNokia upgraded to Hold from Sell at Nordea
Subscribe for More Information
07:55 EDTNOKSeveral telecom equipment stocks attractive after pullback, says Bernstein
Bernstein says that Ericsson (ERIC), Nokia (NOK), and Alcatel-Lucent (ALU) have fallen about 10% recently, even though all three have "limited exposure" to China, according to the firm. The firm adds that all three are defensive in relation to macro economic growth. It keeps Outperform ratings on all three names.
07:34 EDTGSKAdaptimmune expands trial of T-cell therapy for synovial sarcoma
Adaptimmune Therapeutics (ADAP) announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients. Based on encouraging results in the first cohort of 10 patients, presented at the American Association for Cancer Research annual meeting in April 2015, the trial is being expanded to encompass an additional 20 patients in two further cohorts. The expansion of Adaptimmune's trial also triggers two milestone payments from GlaxoSmithKline (GSK). Adaptimmune is collaborating with GSK for the development of its NY-ESO TCR program through a strategic cancer immunotherapy partnership announced in June 2014. Under the terms of the agreement, GSK has an exclusive option to license Adaptimmune's NY-ESO TCR therapeutic and upon exercise would assume full responsibility for further development and commercialization of the therapeutic. Adaptimmune's clinical study includes synovial sarcoma patients who have received standard first line therapy containing ifosfamide and/or doxorubicin and who are intolerant or no longer responding to the regimen, and whose tumor expresses a tumor antigen known as NY-ESO-1. The NY-ESO-1 antigen is believed to be present in 60 to 70 percent of synovial sarcoma patients.The primary objectives of the study are to determine the safety of adoptively transferred autologous T cells expressing an affinity enhanced T cell receptor that recognizes the NY-ESO-1 antigen in HLA-A*0201, HLA-A*0205, and/or HLA-A*0206 positive patients with unresectable, metastatic or recurrent synovial sarcoma. Secondary objectives include the determination of efficacy through response rate and duration of response.
August 31, 2015
06:24 EDTNOKCCI charges Google with abusing market dominance, Economic Times reports
The Competition Commission of India is charging Google (GOOG) with abusing its dominant market position by rigging search results, a claim corroborated by Flipkart, Facebook (FB), Nokia's (NOK) maps division, MakeMy-Trip.com (MMYT), and several other companies, the Economic Times reports. The case marks the first globally where an antitrust body is formally raising such charges against Google, the report says. CCI might impose a fine of up to 10% of Google's income, the report says. Reference Link
06:10 EDTUBSBanks lobby EU over privacy rules overhaul, FT reports
Subscribe for More Information
August 28, 2015
06:19 EDTNOKNokia and China Huaxin sign MOU to create new venture
Nokia and China Huaxin Post & Telecommunication Economy Development Center have signed a memorandum of understanding confirming their intention to combine Nokia's telecommunications infrastructure businesses in China and Alcatel-Lucent Shanghai Bell into a new joint venture. As agreed under the MoU, Nokia expects to hold 50% plus one share in the new joint venture, with China Huaxin holding the remaining shares. Fair value compensation would be received for the contribution of relevant assets to the joint venture. The new joint venture is conditional on and would be formed after the closing of Nokia's planned combination with Alcatel-Lucent, at which point Nokia would own 50% plus one share of ASB. The new joint venture is expected to be a strong national asset based in China capable of delivering value for both parties.Nokia China and ASB are leaders in the Chinese telecommunications infrastructure market and both are long-standing contributors to the development of China and innovation in the country. The new joint venture would have one board of directors, one management team, unified customer and business functions, and one integrated product portfolio and R&D platform. Until the closing of the proposed combination between Nokia and Alcatel-Lucent, Nokia China and ASB will continue to operate as two independent companies.
August 27, 2015
18:02 EDTUBSU.S. may prohibit Deutsche Bank, others from managing pensions, Bloomberg says
In correspondence dated mid-July, the U.S. Labor Department tentatively rejected requests from Deutsche Bank (DB), UBS (UBS), RBS (RBS) to manage U.S. pension funds, reports Bloomberg, citing letters between the organizations. Bloomberg notes that the Department could use the "threat of denial" to mandate stricter conditions on pension management. Reference Link
06:23 EDTUBSGoldman hiring 'several hundred' employees for Warsaw units, Reuters reports
Subscribe for More Information
August 26, 2015
17:06 EDTGSKGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
August 24, 2015
13:15 EDTGSKFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
August 21, 2015
12:18 EDTNOKMicrosoft to cut up to 2,300 jobs in Finland, Reuters reports
Microsoft (MSFT) will cut up to 2,300 jobs in Finland and close Nokia's (NOK) former handset product development unit in Salo, Reuters reports. The cuts are part of Microsoft's plans to cut 7,800 jobs globally. Microsoft will keep open sites in Espoo and Tampere. Reference Link
05:25 EDTGSKNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
August 20, 2015
05:46 EDTNOKNokia Networks expand use of WANdisco big data technology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use